{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:43:04Z","timestamp":1793295784649,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14546-6","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T08:00:30Z","timestamp":1752912030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS)"],"prefix":"10.1186","volume":"25","author":[{"given":"Shanshan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ente","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"issue":"10400","key":"14546_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, et al. Cutaneous melanoma. Lancet. 2023;402(10400):485\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(23)00821-8.","journal-title":"Lancet"},{"key":"14546_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2021","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2021;40:127\u201337. https:\/\/doi.org\/10.1200\/JCO.21.02229.","journal-title":"J Clin Oncol"},{"key":"14546_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37:537\u201346. https:\/\/doi.org\/10.1200\/JCO.18.00149.","journal-title":"J Clin Oncol"},{"key":"14546_CR4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:888\u201398. https:\/\/doi.org\/10.1016\/S1470-2045(22)00290-X.","journal-title":"Lancet Oncol"},{"key":"14546_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33:929\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.519.","journal-title":"Ann Oncol"},{"key":"14546_CR6","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"key":"14546_CR7","doi-asserted-by":"publisher","first-page":"956090","DOI":"10.3389\/fimmu.2022.956090","volume":"13","author":"J-L Huo","year":"2022","unstructured":"Huo J-L, Wang Y-T, Fu W-J, et al. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022;13:956090. https:\/\/doi.org\/10.3389\/fimmu.2022.956090.","journal-title":"Front Immunol"},{"key":"14546_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang H, Dai Z, Wu W, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40: 184. https:\/\/doi.org\/10.1186\/s13046-021-01987-7.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"14546_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"issue":"1","key":"14546_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"issue":"1","key":"14546_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med"},{"key":"14546_CR12","unstructured":"NationalComprehensiveCancerNetwork. Inc:NCCNClinicalPracticeGuidelines inOncology(NCCNGuidelines) forMelanoma:Cutaneous(V.2.2024).2024. 2024.http:\/\/NCCN.org"},{"key":"14546_CR13","doi-asserted-by":"publisher","first-page":"160026","DOI":"10.1038\/sdata.2016.26","volume":"3","author":"JM Banda","year":"2016","unstructured":"Banda JM, Evans L, Vanguri RS, et al. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3:160026. https:\/\/doi.org\/10.1038\/sdata.2016.26.","journal-title":"Sci Data"},{"key":"14546_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Noren","year":"2013","unstructured":"Noren GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369. https:\/\/doi.org\/10.1177\/0962280211403604.","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"14546_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14740338.2023.2251382","volume":"23","author":"S-P Zou","year":"2024","unstructured":"Zou S-P, Yang H-Y, Ouyang M, et al. Postmarketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA adverse event reporting system (FAERS). Expert Opin Drug Saf. 2024;23(3):353\u201362. https:\/\/doi.org\/10.1080\/14740338.2023.2251382.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"14546_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5539\/cco.v3n1p30","volume":"3","author":"T Khurram","year":"2014","unstructured":"Khurram T, Arezo F, Fauzia R. Cutaneous melanoma at an inner City university program and the need for aggressive public awareness programs: A pilot. Twelve Year Rev Cancer Clin Oncol. 2014;3(1):30\u20135. https:\/\/doi.org\/10.5539\/cco.v3n1p30.","journal-title":"Twelve Year Rev Cancer Clin Oncol"},{"issue":"7","key":"14546_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2340\/00015555-2944","volume":"98","author":"S Ribero","year":"2018","unstructured":"Ribero S, Stucci LS, Marra E, et al. Effect of age on melanoma risk, prognosis and treatment response. Acta Derm Venereol. 2018;98(7):624\u20139. https:\/\/doi.org\/10.2340\/00015555-2944.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"14546_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejca.2019.08.027","volume":"121","author":"P Corbaux","year":"2019","unstructured":"Corbaux P, Maillet D, Boespflug A, et al. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. Eur J Cancer. 2019;121(1):192\u2013201. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.027.","journal-title":"Eur J Cancer"},{"issue":"3","key":"14546_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jgo.2018.07.015","volume":"10","author":"J Sattar","year":"2019","unstructured":"Sattar J, Kartolo A, Hopman WM, et al. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population. J Geriatr Oncol. 2019;10(3):411\u20134. https:\/\/doi.org\/10.1016\/j.jgo.2018.07.015.","journal-title":"J Geriatr Oncol"},{"issue":"12","key":"14546_CR20","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","volume":"7","author":"CA Nebhan","year":"2021","unstructured":"Nebhan CA, Cortellini A, Ma W, et al. Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study. JAMA Oncol. 2021;7(12):1856\u201361. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4960.","journal-title":"JAMA Oncol"},{"issue":"14","key":"14546_CR21","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-23-2396","volume":"30","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Hu Z, Bathena SP, et al. Model-informed clinical pharmacology profile of a novel fixed-dose combination of nivolumab and relatlimab in adult and adolescent patients with solid tumors. Clin Cancer Res. 2024;30(14):3050\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2396.","journal-title":"Clin Cancer Res"},{"issue":"33","key":"14546_CR22","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1200\/JCO.24.01125","volume":"42","author":"GV Long","year":"2024","unstructured":"Long GV, Lipson EJ, Hodi FS, et al. First-line nivolumab plus relatlimab versus nivolumab plus ipilimumab in advanced melanoma: an indirect treatment comparison using RELATIVITY-047 and CheckMate 067 trial data. J Clin Oncol. 2024;42(33):3926\u201334. https:\/\/doi.org\/10.1200\/JCO.24.01125.","journal-title":"J Clin Oncol"},{"key":"14546_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2023.04.010","volume":"188","author":"A Boutros","year":"2023","unstructured":"Boutros A, Tanda ET, Croce E, et al. Activity and safety of first-line treatments for advanced melanoma: a network meta-analysis. Eur J Cancer. 2023;188:64\u201379. https:\/\/doi.org\/10.1016\/j.ejca.2023.04.010.","journal-title":"Eur J Cancer"},{"key":"14546_CR24","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S196316","author":"H Xu","year":"2019","unstructured":"Xu H, Tan P, Zheng X, et al. Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis. Drug Des Devel Ther. 2019. https:\/\/doi.org\/10.2147\/DDDT.S196316.","journal-title":"Drug Des Devel Ther"},{"issue":"50","key":"14546_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009262","volume":"96","author":"JH Chen","year":"2017","unstructured":"Chen JH, Lee KY, Hu CJ, et al. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore). 2017;96(50): e9262. https:\/\/doi.org\/10.1097\/MD.0000000000009262.","journal-title":"Medicine (Baltimore)"},{"issue":"19","key":"14546_CR26","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801. https:\/\/doi.org\/10.1056\/NEJMoa1802357.","journal-title":"N Engl J Med"},{"issue":"11","key":"14546_CR27","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia Gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127\u201334. https:\/\/doi.org\/10.1212\/WNL.0000000000004359.","journal-title":"Neurology"},{"key":"14546_CR28","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.2147\/CMAR.S185202","volume":"11","author":"R Martin Huertas","year":"2019","unstructured":"Martin Huertas R, Saavedra Serrano C, Perna C, et al. Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges. Cancer Manag Res. 2019;11:4541\u20138. https:\/\/doi.org\/10.2147\/CMAR.S185202.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"14546_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2020.790","volume":"53","author":"SQ Tang","year":"2021","unstructured":"Tang SQ, Tang LL, Mao YP, et al. The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. Cancer Res Treat. 2021;53(2):339\u201354. https:\/\/doi.org\/10.4143\/crt.2020.790.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"14546_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407417. Epub 2024 Sep 15.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14546-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14546-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14546-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T08:00:32Z","timestamp":1752912032000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14546-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14546"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14546-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6426078\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Ethical approval was not required for this study because we used the FAERS database, which is a free open-access database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1190"}}